Literature DB >> 23322501

Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.

Masami Tanaka, Kwiyoung Park, Keiko Tanaka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322501     DOI: 10.1177/1352458512472750

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

1.  Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Authors:  Loredana La Mantia; Valentina Prone; Maria Raffaella Marazzi; Cristina Erminio; Alessandra Protti
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

2.  Assessment of safety and effectiveness of oral multiple sclerosis medication.

Authors:  Abdulrahman M Al Turaiki; Maha A Al Ammari; Dalal A Alabdulkarim; Abdullah U Althemery
Journal:  Saudi Med J       Date:  2019-11       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.